Washington, DC (PRWEB) June 04, 2011
SRxA Strategic Pharmaceutical Advisors, LLC, a leading healthcare consulting, marketing and education firm, is pleased to announce that it has entered into an agreement with the Executive Directors and organizers of the International Eosinophil Society, Inc. (IES) to become the exclusive provider of rapid dissemination post-symposium e-Newsletter.
The IES Biennial Symposium provides a venue for scientists and clinician-investigators interested in eosinophils to meet, exchange information and develop collaborations to advance research in the fields of eosinophil biology and the pathogenesis of eosinophil-associated allergic and other diseases. The symposium showcases new research findings related to the production of eosinophils, their trafficking, their effector functions, the use of animal models to explore the importance and role of the eosinophil in health and disease, translational studies of animal model findings into patient-oriented research, and the development of new therapies of eosinophil-associated diseases.
The 2011 7th IES Biennial Symposium will be held from June 21-25 in Quebec City. While attendance of the symposium attracts approximately 200, IES recognizes that there are thousands of other pulmonologists, infectious disease specialists, allergists, rheumatologists, hematologists and immunologists who see or treat patients with eosinophil-associated diseases.
To this end, SRxA and its team of independent Clinical Advisors will develop, produce and distribute an interactive e-Newsletter within four weeks of the Symposium. The e-Newsletter will feature a blend of scientific session reviews, “hot topic” discussions, key takeaway messages, and other pertinent information. This will be distributed electronically to more than 10,000 U.S.-based health professionals.
Publication and distribution of the e-Newsletter will include the support of multiple pharmaceutical and device industry sponsors, who will be prominently acknowledged. Sponsorship efforts are ongoing.
“This electronic newsletter will enable us to reach a much wider audience than we have previously been able to address due to the capacity of the live event. It will be a perfect complement to the program and will provide both attendees and non-attendees with a glimpse into the IES Biennial Symposium. SRxA was the natural choice as a partner in this endeavor because of the depth of their knowledge and expertise in eosinophil disorders and their unique ability to produce informative and intriguing peer-reviewed, rapid electronic publications following scientific congresses,” said IES President Dr. James J. Lee.
“We are delighted to work with Dr. Lee and the Executive Director of IES to develop and produce a unique vehicle that will distribute pertinent information in a timely fashion to the medical communities they serve,” commented Christos Efessiou, PhD, SRxA’s Chief Executive Officer.
SRxA operates on a unique business model that utilizes independent clinical teams of national and international Key Opinion Leaders who advise pharmaceutical and medical device clients in research, clinical, regulatory, education and business matters. SRxA advisory groups focus in key therapeutic areas such as Allergy, Otolaryngology, Pulmonary Diseases, Respiratory Medicine (Europe), Ophthalmology, Health Outcomes, Reproductive Endocrinology and Genetics, Aesthetics, and Behavioral Health. The company is headquartered in Washington, DC with offices in London and Hong Kong.
For more information, please contact Judi Miller at 202.316.8692, jmiller(at)SRxA(dot)com, or visit http://www.srxa.com.